Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

Proudfoot, Rebecca; Phillips, Bob; Wilne, Sophie

doi:10.1097/mph.0000000000000771

Cited by 21 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Selective blockade of central 5-HT3-recep-tors, e. g. ondansetron 5 mg/m² every 8-12 h starting before chemotherapy, is suggested for carboplatin administration. ▪ Pneumocystis jiroveci prophylaxis is recommended and will be most often the prescription of cotrimoxazole (5-6 mg/kg TMP or 30 mg/kg SMZ bid per day) on two to three consecutive days per week [102]. ▪ The use of granulocyte colony stimulating factors is not routinely recommended.…”

Section: Supportive Carementioning

confidence: 99%

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma

et al. 2019

View full text Add to dashboard Cite

Low grade gliomas (LGGs) constitute the largest, yet clinically and (molecular-) histologically heterogeneous group of pediatric brain tumors of WHO grades I and II occurring throughout all pediatric age groups and at all central nervous system (CNS) sites. The tumors are characterized by a slow growth rate and may show periods of growth arrest. Around 40% of all LGG patients can be cured by complete neurosurgical resection and are followed by close observation. In case of relapse, second resection often is possible. Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms. This also applies to patients with a diagnosis of LGG on the basis of radiological criteria. By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy. Overall survival is around 90%, and many patients survive with residual tumor, i. e. they suffer from chronic disease. All patients need comprehensive neuro-oncological care, the principles and details of which are summarized in the current guidelines. These represent standard of care for diagnostic work-up (including neuroimaging and neuropathology), and for therapeutic decisions (including the indications to non-surgical treatment) as well as concepts for neurosurgical intervention, chemotherapy and radiotherapy as well as surveillance and rehabilitation. The current treatment algorithm was compiled by members of the LGG working group of the SIOP-E brain tumor group (SIOP-E-BTG) and is based upon the results of previous European LGG studies and international reports.

show abstract

Section: Supportive Carementioning

confidence: 99%

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The other pediatric-specific CPGs addressed: antifungal prophylaxis,[28] prevention of mucositis[30] and prevention of Pneumocytis jirovecii pneumonia in children with solid tumours. [29]…”

Section: Resultsmentioning

confidence: 99%

“…Of the 22 papers that met eligibility criteria, 13 were specific to the pediatric population. [18][19][20][21][22][23][24][25][26][27][28][29] The remaining nine CPGs included recommendations for both adult and pediatric patients ( Table 5). Almost one-third (7/22) of the included CPGs were focused on various aspects of chemotherapy-induced nausea and vomiting (CINV), of which five made exclusively pediatric recommendations.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group

Seelisch

Sung

Kelly

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Providing evidence-based supportive care for children with cancer has the potential to optimize treatment outcomes and improve quality of life. The Children’s Oncology Group (COG) Supportive Care Guidelines sub-Committee conducted a systematic review to identify current supportive care clinical practice guidelines (CPGs) relevant to childhood cancer or pediatric hematopoietic stem cell transplant. Only 22 papers met the 2011 Institute of Medicine criteria to be considered a CPG. The results highlight the paucity of CPGs available to pediatric oncology healthcare professionals and the pressing need to create CPGs using current methodological standards.

show abstract

“…Pneumocystis jirovecii pneumonia (PJP) classically develops in immunocompromised hosts with acquired immunodeficiency syndrome (AIDS), prolonged corticosteroid exposure, or other disorders of T-cell function [24,25,26,27]. Patients typically present with dyspnea, non-productive cough, and fever in the setting of diffuse ground glass opacities on chest radiograph [27,28].…”

Section: (1→3)-β-d-glucan (Bdg) In Serummentioning

confidence: 99%

Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses

McCarthy

Petraitienė

Walsh

2017

IJMS

View full text Add to dashboard Cite

Early diagnosis and prompt initiation of appropriate antimicrobial therapy are crucial steps in the management of patients with invasive fungal infections. However, the diagnosis of invasive mycoses remains a major challenge in clinical practice, because presenting symptoms may be subtle and non-invasive diagnostic assays often lack sensitivity and specificity. Diagnosis is often expressed on a scale of probability (proven, probable and possible) based on a constellation of imaging findings, microbiological tools and histopathology, as there is no stand-alone assay for diagnosis. Recent data suggest that the carbohydrate biomarker (1→3)-β-d-glucan may be useful in both the diagnosis and therapeutic monitoring of invasive fungal infections due to some yeasts, molds, and dimorphic fungi. In this paper, we review recent advances in the use of (1→3)-β-d-glucan to monitor clinical response to antifungal therapy and explore how this assay may be used in the future.

show abstract

Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

Cited by 21 publications

References 63 publications

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma

Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group

Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses

Contact Info

Product

Resources

About